PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -32.93 Billion KRW | -434.44% |
| 2022 | -6.16 Billion KRW | -125.75% |
| 2021 | 23.93 Billion KRW | 320.29% |
| 2020 | 5.69 Billion KRW | 372.66% |
| 2019 | 1.2 Billion KRW | 264.27% |
| 2018 | -733.51 Million KRW | 96.39% |
| 2017 | -20.34 Billion KRW | 8.1% |
| 2016 | -22.13 Billion KRW | -56.18% |
| 2015 | -14.17 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -78.58 Billion KRW | -138.59% |
| 2024 Q2 | -59.21 Billion KRW | 23.62% |
| 2023 FY | -32.93 Billion KRW | -434.44% |
| 2023 Q2 | -16.94 Billion KRW | -31.37% |
| 2023 Q1 | -12.9 Billion KRW | -109.32% |
| 2023 Q3 | -30.04 Billion KRW | -77.29% |
| 2023 Q4 | -32.93 Billion KRW | -9.62% |
| 2022 Q3 | 33.53 Billion KRW | 9.2% |
| 2022 Q4 | -6.16 Billion KRW | -118.38% |
| 2022 FY | -6.16 Billion KRW | -125.75% |
| 2022 Q2 | 30.71 Billion KRW | 23.81% |
| 2022 Q1 | 24.8 Billion KRW | 3.63% |
| 2021 FY | 23.93 Billion KRW | 320.29% |
| 2021 Q1 | -19.88 Billion KRW | -534.37% |
| 2021 Q4 | 23.93 Billion KRW | 326.95% |
| 2021 Q3 | -10.54 Billion KRW | -1070.29% |
| 2021 Q2 | -901.23 Million KRW | 95.47% |
| 2020 Q3 | 11.55 Billion KRW | 148.97% |
| 2020 FY | 5.69 Billion KRW | 372.66% |
| 2020 Q4 | 4.57 Billion KRW | -60.36% |
| 2020 Q1 | 1.01 Billion KRW | 19.88% |
| 2020 Q2 | -23.58 Billion KRW | -2424.0% |
| 2019 Q3 | -2.88 Billion KRW | 63.54% |
| 2019 FY | 1.2 Billion KRW | 264.27% |
| 2019 Q4 | 846.59 Million KRW | 129.34% |
| 2019 Q2 | -7.91 Billion KRW | -170.31% |
| 2019 Q1 | -2.92 Billion KRW | -283.77% |
| 2018 Q1 | 920.67 Million KRW | 105.42% |
| 2018 FY | -733.51 Million KRW | 96.39% |
| 2018 Q4 | -762.7 Million KRW | -125.84% |
| 2018 Q3 | 2.95 Billion KRW | 118.46% |
| 2018 Q2 | -15.99 Billion KRW | -1837.15% |
| 2017 Q3 | -28.72 Billion KRW | -48.34% |
| 2017 Q2 | -19.36 Billion KRW | -11.18% |
| 2017 Q1 | -17.41 Billion KRW | 1.22% |
| 2017 Q4 | -16.99 Billion KRW | 40.86% |
| 2017 FY | -20.34 Billion KRW | 8.1% |
| 2016 Q3 | -22.68 Billion KRW | 0.0% |
| 2016 Q1 | 123.04 Billion KRW | 1400.4% |
| 2016 Q4 | -17.63 Billion KRW | 22.26% |
| 2016 FY | -22.13 Billion KRW | -56.18% |
| 2015 FY | -14.17 Billion KRW | 0.0% |
| 2015 Q4 | -9.46 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 28.679% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 18.841% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 172.636% |
| Bioneer Corporation | -3.9 Billion KRW | -742.891% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 494.387% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 322.342% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 466.312% |
| Helixmith Co., Ltd | -24.42 Billion KRW | -34.851% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 108.469% |
| Medy-Tox Inc. | 49.58 Billion KRW | 166.429% |
| Peptron, Inc. | 4.86 Billion KRW | 776.544% |
| Amicogen, Inc. | 125.26 Billion KRW | 126.295% |
| Genexine, Inc. | 61.39 Billion KRW | 153.649% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | -140.659% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 41.238% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 161.487% |
| SillaJen, Inc. | -13.89 Billion KRW | -137.11% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 139.082% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 220.324% |
| Genomictree Inc. | -43.43 Billion KRW | 24.166% |
| MedPacto, Inc. | -64 Billion KRW | 48.534% |
| D&D Pharmatech | -7.5 Billion KRW | -338.722% |
| EASY BIO,Inc. | 53.21 Billion KRW | 161.902% |
| GI Innovation, Inc. | -4.82 Billion KRW | -583.014% |